Example: Heart Attack

Clinical Trials on Myxoid Liposarcoma

Total 24 results





    • NCT00633165
      Unknown status
      Brostallicin Clinical Trial for Myxoid Liposarcoma
      Conditions: Myxoid Liposarcoma
    • NCT03816475
      Active, not recruiting
      Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall (LIPO-MYX Trial)
      Conditions: Myxoid Liposarcoma
    • NCT02106312
      Active, not recruiting
      Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas
      Conditions: Myxoid Liposarcoma of Soft Tissue
    • NCT04044768
      Recruiting
      Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
      Conditions: Synovial Sarcoma; Myxoid Liposarcoma
    • NCT02821507
      Recruiting
      Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
      Conditions: Conventional Chondrosarcoma; Myxoid Liposarcoma; Mesenchymal Chondrosarcoma; Dedifferentiated Chondrosarcoma
    • NCT01957709
      Terminated
      Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma
      Conditions: Myxoid Liposarcoma; Round Cell Liposarcoma; Synovial Sarcoma
    • NCT02249949
      Active, not recruiting
      Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery
      Conditions: Liposarcoma
    • NCT02059850
      Withdrawn
      NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
      Conditions: Adult Synovial Sarcoma; Myxoid/Round Cell Liposarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
    • NCT00579501
      Completed
      Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma
      Conditions: Liposarcoma,Myxoid
    • NCT02992743
      Recruiting
      A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma
      Conditions: Neoplasms
    • NCT04356872
      Recruiting
      The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma
      Conditions: Sarcoma, Soft Tissue
    • NCT03450122
      Recruiting
      Modified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent Sarcoma
      Conditions: HLA-A*0201 Positive Cells Present; NY-ESO-1 Positive Tumor Cells Present; Recurrent Myxoid Liposarcoma; Recurrent Synovial Sarcoma
    • NCT01477021
      Completed
      Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
      Conditions: Adult Liposarcoma; Adult Synovial Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma; Stage IV Adult Soft Tissue Sarcoma
    • NCT03397186
      Withdrawn
      Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma
      Conditions: Myxoid Liposarcoma; Round Cell Liposarcoma; Stage III Soft Tissue Sarcoma AJCC v7; Stage IV Soft Tissue Sarcoma AJCC v7; Metastatic Soft Tissue Sarcoma; Unresectable Soft Tissue Sarcoma
    • NCT03399448
      Terminated
      NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
      Conditions: Multiple Myeloma; Melanoma; Synovial Sarcoma; Myxoid/Round Cell Liposarcoma
    • NCT03670069
      Recruiting
      Itacitinib in Treating Patients With Refractory Metastatic/Advanced Soft Soft Tissue Sarcomas
      Conditions: Metastatic Leiomyosarcoma; Metastatic Synovial Sarcoma; Metastatic Undifferentiated Pleomorphic Sarcoma; Advanced Myxoid Liposarcoma; Advanced Soft Tissue Sarcoma; Metastatic Myxoid Liposarcoma; Metastatic Round Cell Liposarcoma; Metastatic Soft Tissue Sarcoma; Refractory Leiomyosarcoma; Refractory Myxoid Liposarcoma; Refractory Round Cell Liposarcoma; Refractory Soft Tissue Sarcoma; Refractory Synovial Sarcoma; Refractory Undifferentiated Pleomorphic Sarcoma; Advanced Leiomyosarcoma; Advanced Synovial Sarcoma; Advanced Undifferentiated Pleomorphic Sarcoma
    • NCT03063632
      Active, not recruiting
      Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
      Conditions: Metastatic Myxoid Liposarcoma; Metastatic Round Cell Liposarcoma; Metastatic Synovial Sarcoma; Recurrent Mycosis Fungoides and Sezary Syndrome; Refractory Mycosis Fungoides and Sezary Syndrome; Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7; Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7; Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7; Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7; Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7; Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7; Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7; Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7; Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7; Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7; Unresectable Synovial Sarcoma
    • NCT03989596
      Recruiting
      Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
      Conditions: Sarcoma; Alveolar Soft Part Sarcoma; Clear Cell Sarcoma; Malignant Peripheral Nerve Sheath Tumors; Myxoid Liposarcoma; Liposarcoma, Dedifferentiated; Synovial Sarcoma; Leiomyosarcoma; Undifferentiated Pleomorphic Sarcoma; Fibrosarcoma; Pleomorphic Rhabdomyosarcoma
    • NCT03651375
      Active, not recruiting
      Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
      Conditions: Sarcoma; Fibrosarcoma; Leiomyosarcoma; Liposarcoma; Myosarcoma; Histiocytic Sarcoma; Synovial Sarcoma; Lymphangiosarcoma; Malignant Peripheral Nerve Sheath Tumors; Myxofibrosarcoma; Myxoid Liposarcoma; Undifferentiated Sarcoma; Pleomorphic Liposarcoma; Undifferentiated Pleomorphic Sarcoma; Dedifferentiated Liposarcoma; Pleomorphic Rhabdomyosarcoma; Malignant Triton Tumor
    • NCT04044859
      Recruiting
      Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
      Conditions: Synovial Sarcoma; Myxoid/Round Cell Liposarcoma (MRCLS); Melanoma; Urothelial Carcinoma; Head and Neck; Ovarian; Gastric Cancer; Esophagogastric Junction Disorder; Nonsmall Cell Lung Cancer; Esophageal Cancer
    • NCT02609984
      Terminated
      Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)
      Conditions: Sarcoma; Myxoid/Round Cell Liposarcoma; Synovial Sarcoma; Metastatic Sarcoma; Recurrent Adult Soft Tissue Sarcoma; Locally Advanced Sarcoma; Liposarcoma
    • NCT03132922
      Recruiting
      MAGE-A4ᶜ¹º³²T for Multi-Tumor
      Conditions: Urinary Bladder Cancer; Melanoma; Head and Neck Cancer; Ovarian Cancer; Non-Small Cell Lung Cancer; Esophageal Cancer; Gastric Cancer; Synovial Sarcoma; Myxoid Round Cell Liposarcoma; Gastroesophageal Junction
    • NCT04512495
      Recruiting
      Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma?
      Conditions: Sarcoma
    • NCT02210104
      Withdrawn
      Adoptive Therapy Using Antigen-Specific CD4 T-Cells
      Conditions: Melanoma; Sarcoma
      Medical Conditions
      Sponsors and Collaborators
      Drug Interventions
      Conditions
      Rare Diseases
      Drug Interventions
      Dietary Supplements
      Sponsor/Collaborators
      Locations